Citation Impact
Citing Papers
Activation of Drosophila Toll During Fungal Infection by a Blood Serine Protease
2002 StandoutScienceNobel
Efficacy and Safety of the Novel Oral Anticoagulants in Atrial Fibrillation
2012
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
2015 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary
2014 Standout
Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report
2016 Standout
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
2013 Standout
Injectable antibacterial conductive nanocomposite cryogels with rapid shape recovery for noncompressible hemorrhage and wound healing
2018 Standout
Parenteral Anticoagulants
2012 Standout
Antithrombotic Therapy for Venous Thromboembolic Disease
2008 Standout
The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: Insights from genetic studies
2000
New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding: A Systematic Review and Meta-analysis
2013
Complement and its role in innate and adaptive immune responses
2009 Standout
Silk-based biomaterials
2002 Standout
Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor
2010
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
2014 Standout
Effect on perfusion chamber thrombus size in patients with atrial fibrillation during anticoagulant treatment with oral direct thrombin inhibitors, AZD0837 or ximelagatran, or with vitamin K antagonists
2011
Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
2010
New Antithrombotic Drugs
2008
Oral Anticoagulant Therapy
2012 Standout
New Antithrombotic Drugs
2012
Antithrombotic Therapy for VTE Disease
2016 Standout
Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development
2008
Antithrombotic Therapy for Coronary Artery Disease
2004
Treatment and Prevention of Heparin-Induced Thrombocytopenia
2008 Standout
Edoxaban for the long‐term treatment of venous thromboembolism: rationale and design of the Hokusai‐venous thromboembolism study – methodological implications for clinical trials
2013
Evolution of enzyme cascades from embryonic development to blood coagulation
2002
Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension1
2002
Heat Shock Protein A12B Protects Vascular Endothelial Cells Against Sepsis-Induced Acute Lung Injury in Mice
2017 Standout
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
2013 Standout
Angiogenesis in health and disease
2003 Standout
Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti‐FXa assays
2014 StandoutNobel
Complement: a key system for immune surveillance and homeostasis
2010 Standout
Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial
2015
Measuring reactive species and oxidative damagein vivoand in cell culture: how should you do it and what do the results mean?
2004 Standout
Platelet Activation and Atherothrombosis
2007 Standout
The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism
2010
The role of thrombin receptors PAR1 and PAR4 for PAI-1 storage, synthesis and secretion by human platelets
2012 StandoutNobel
ANTITHROMBOTIC ACTIONS OF SELECTIVE INHIBITORS OF BLOOD COAGULATION FACTOR Xa IN RAT MODELS OF THROMBOSIS
1996
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement
2010
Heparin-Induced Thrombocytopenia
2006 Standout
Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation
2005
Highly Stereoselective Biocatalytic Synthesis of Key Cyclopropane Intermediate to Ticagrelor
2016 StandoutNobel
Prevention of Venous Thromboembolism
2004 Standout
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)
2010
Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure<SUBTITLE>The EVEREST Outcome Trial</SUBTITLE>
2007 Standout
Complement and coagulation: strangers or partners in crime?
2007
The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition
2016 Standout
Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) Versus Warfarin in Patients With Atrial Fibrillation
2012
Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians
2017
Effects of the Oral, Direct Factor Xa Inhibitor Rivaroxaban on Platelet‐Induced Thrombin Generation and Prothrombinase Activity1
2007
Idarucizumab for Dabigatran Reversal
2015 Standout
Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification
2010
The creation of an antithrombotic surface by apyrase immobilization
2010 StandoutNobel
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa
2013
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation
2013
Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy
2009 Standout
Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: Thrombin or factor-Xa inhibitors. Recommendations of the Working Group on perioperative haemostasis and the French Study Group on thrombosis and haemostasis
2011
Correlation of Coagulation Markers and 4F-PCC-Mediated Reversal of Rivaroxaban in a Rabbit Model of Acute Bleeding
2015
Novel oral anticoagulants: clinical pharmacology, indications and practical considerations
2013
Reversal of New, Factor-specific Oral Anticoagulants by rFVIIa, Prothrombin Complex Concentrate and Activated Prothrombin Complex Concentrate: A Review of Animal and Human Studies
2014
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitor
2005
Comparative Metabolism of 14C-Labeled Apixaban in Mice, Rats, Rabbits, Dogs, and Humans
2009
A dose‐ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty
2010
Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays
2010 StandoutNobel
A practical guide to hydrogels for cell culture
2016 Standout
Reassessment of Dobutamine, Dopamine, and Milrinone in the Management of Acute Heart Failure Syndromes
2005
Thrombosis as an intravascular effector of innate immunity
2012 Standout
Comparison of Antithrombin Activity of the Polysulphate Chitosan Derivatives in In Vivo and In Vitro System
2001
Fibrin-based biomaterials: Modulation of macroscopic properties through rational design at the molecular level
2013
Cancer-associated thrombosis: investigating the role of new oral anticoagulants
2015
Guidelines for the Early Management of Adults With Ischemic Stroke
2007 Standout
Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy
2018
Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and -independent mechanisms
1994
The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
2004
Factor Xa Inhibitors: Next-Generation Antithrombotic Agents
2010
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2019 Standout
Clot contraction: compression of erythrocytes into tightly packed polyhedra and redistribution of platelets and fibrin
2013
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
2010 Standout
Synthetic approaches to the 2011 new drugs
2013
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons
2019 Standout
mTOR-dependent synthesis of Bcl-3 controls the retraction of fibrin clots by activated human platelets
2006
Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial
2016
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2020 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
Protease Inhibitors: Current Status and Future Prospects
2000
Mechanisms of Diabetic Complications
2013 Standout
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
The Host Defense of Drosophila melanogaster
2007 StandoutNobel
Solid-Phase Library Synthesis, Screening, and Selection of Tight-Binding Reduced Peptide Bond Inhibitors of a RecombinantLeishmaniamexicanaCysteine Protease B
2002 StandoutNobel
Evolving use of new oral anticoagulants for treatment of venous thromboembolism
2014
Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and -independent mechanisms
1994
Synthesis and Conformational Analysis of a Non-Amidine Factor Xa Inhibitor That Incorporates 5-Methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine as S4 Binding Element
2004
Natural Products as Sources of New Drugs from 1981 to 2014
2016 Standout
Quantitative high performance liquid chromatography/tandem mass spectrometric analysis of the four classes of F 2 -isoprostanes in human urine
1999
From 2000 to Mid-2010: A Fruitful Decade for the Synthesis of Pyrazoles
2011 Standout
Discovery of 1-(2-Aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2‘-(aminosulfonyl)[1,1‘-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor
2003
Rivaroxaban: A New Oral Factor Xa Inhibitor
2010
Chitosan Chemistry and Pharmaceutical Perspectives
2004 Standout
Irreversible Inhibitors of Serine, Cysteine, and Threonine Proteases
2002 Standout
Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design
2011 Standout
Works of Satoshi Kunitada being referenced
A prostacyclin analog impairs the response to tissue-type plasminogen activator during coronary thrombolysis: evidence for a pharmacokinetic interaction.
1991
A Synthetic Inhibitor of Factor Xa, DX-9065a, Reduces Proliferation of Vascular Smooth Muscle Cells in Vivo in Rats
2000
Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber
2007
Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation
2010
Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers
1999
Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation
2012
Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor
1995
Effects of Food on the Pharmacokinetics of Edoxaban, an Oral Direct Factor Xa Inhibitor, in Healthy Volunteers
2010
A thromboxane A2 synthetase inhibitor retards hypertensive rat diabetic nephropathy
1992
Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux
2011
Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers
2010
Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction
1992
Functional and metabolic effects of bucladesine (dibutyryl cyclic AMP) in the working rat heart preparation: comparison with dopamine.
1990
Study of Coagulation and Platelets Response in An Open Label Randomised Non Treatment and Active Controlled (Dalteparin, Ximelagatran and DU- 176b) in 4 Groups of Elderly Healthy Subjects
2008
Randomized, Parallel Group, Multicenter, Multinational Study Evaluating Safety of DU-176b Compared with Warfarin in Subjects with Non-Valvular Atrial Fibrillation
2008
Antithrombotic Effects of DX-9065a, a Direct Factor Xa Inhibitor
2002
Molecular model of an interaction between factor Xa and DX-9065a, a novel factor Xa inhibitor: Contribution of the acetimidoylpyrrolidine moiety of the inhibitor to potency and selectivity for serine proteases
1995
Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction
1992
Antithrombotic Effects of Orally Active Synthetic Antagonist of Activated Factor X in Nonhuman Primates
1995
Antithrombotic and Hemorrhagic Effects of DX-9065a, a Direct and Selective Factor Xa Inhibitor: Comparison with a Direct Thrombin Inhibitor and Antithrombin Ill-Dependent Anticoagulants
1997
Factor Xa Inhibitors
1996
First Experience With Direct Factor Xa Inhibition in Patients With Stable Coronary Disease
2002
Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants.
1997